TSI-GSD-104 is under clinical development by Defender Pharmaceuticals and currently in Phase II for Eastern Equine Encephalitis. According to GlobalData, Phase II drugs for Eastern Equine Encephalitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TSI-GSD-104 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TSI-GSD-104 overview

TSI-GSD-104 is under investigation for the prevention of eastern equine encephalitis. It is administered by subcutaneous route. It is an inactivated, dried vaccine. Vaccine originating from the supernatant harvested from primary chicken embryo cell cultures. The vaccine was prepared from specific pathogen-free eggs infected with the attenuated PE-6 strain of EEE virus.

Defender Pharmaceuticals overview

Defender Pharmaceuticals is a life sciences company focused on discovering, developing and commercializing medicines to patients with strength and security. The company is headquartered in St. Louis, Missouri, the US.

For a complete picture of TSI-GSD-104’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.